Clinical Trial
Published on 13 Jan 2016
Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2015.00301
- 4,867 views
- 11 citations